Eye Drop Preservatives: BAK, Alternatives and the Stability Trade-Offs

Every multidose eye drop bottle faces a fundamental design problem: the moment a patient opens it, the contents begin a weeks-long journey of repeated exposure to air, fingertips and eyelashes. Preservatives exist to keep that bottle microbiologically safe until the last drop. Yet the most widely used preservative in history — benzalkonium chloride (BAK) — is also the most criticised, with decades of evidence linking chronic exposure to ocular surface damage. For ophthalmologists choosing chronic therapies, and for manufacturers formulating them, the preservative question is a genuine trade-off between microbial safety, ocular tolerability and product stability.

This article explains how preservatives work, what the evidence says about BAK, the alternatives available, and what preservative-free really means for stability and cost.

Why Multidose Eye Drops Need Preservatives

Regulatory expectations worldwide — the US FDA, USP and European Pharmacopoeia among them — have required antimicrobial protection in multidose ophthalmic products since the 1970s, and for good reason. Studies of in-use eye drop bottles repeatedly find contamination of dropper tips and caps; a contaminated bottle used after ocular surgery is a direct inoculation route into a vulnerable eye. A preserved multidose bottle must pass a preservative efficacy test (USP <51>, Ph. Eur. 5.1.3, and ISO 14730 for ophthalmics), demonstrating that the formulation can kill defined challenge organisms — Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Candida albicans and Aspergillus species — within specified timeframes.

In short: preservatives are not an optional extra. They are the licence condition for the convenient, economical multidose format.

BAK: The Workhorse and Its Problem

Benzalkonium chloride is a quaternary ammonium detergent used in roughly 70% of ophthalmic formulations, typically at 0.004–0.02%. It earned that dominance honestly: it is broad-spectrum bactericidal (Gram-positive and Gram-negative), active against fungi, water-soluble, inexpensive, chemically stable, and compatible with most actives. It even transiently disrupts corneal epithelial tight junctions, which can enhance penetration of the active drug.

The problem is that the same detergent action hits human cells. The evidence base — summarised in the TFOS DEWS II Iatrogenic Report (Gomes et al., 2017) and reviews by Kahook and others — documents that chronic BAK exposure:

• Disrupts the corneal epithelial barrier and induces epithelial cell apoptosis
• Reduces conjunctival goblet cell density (damaging the mucin layer of the tear film)
• Shortens tear break-up time and lowers Schirmer scores — i.e., causes or worsens dry eye
• Triggers inflammatory pathways on the ocular surface
• Is associated with worse outcomes after subsequent glaucoma filtration surgery, in an exposure-dependent manner

These effects are dose- and duration-dependent. A two-week antibiotic course preserved with BAK is a non-issue for most patients. A glaucoma patient instilling two or three BAK-preserved drops daily for twenty years is a different risk profile entirely — which is why the glaucoma literature drives this debate, and why the EMA added specific BAK labelling requirements in 2017.

The Alternative Preservatives

Formulators have responded with "second-generation" systems designed to keep antimicrobial efficacy while reducing cellular toxicity:

Honesty matters here: alternative preservatives are better studied for tolerability than for equivalence of antimicrobial performance, and reviews note their benefits are not uniformly proven. They also cost more and can complicate formulation compatibility.

The Stability Side of the Equation

Preservative choice is inseparable from stability science:

• Compatibility. Some preservatives bind to container plastics (BAK can adsorb into some polymers), some actives are incompatible with specific preservative ions, and preservative concentration itself must be assayed across shelf life — a preserved drop whose preservative falls below specification is a sterility-assurance failure waiting to happen.
• pH dependence. Many preservative systems work only within a defined pH window, which constrains the buffer system and, in turn, active stability and comfort.
• Packaging interaction. Sorption and leachables studies must cover the preservative as well as the active; container-closure integrity protects both.

This is why changing a preservative is never a "label change" — it is a reformulation requiring new compatibility, preservative efficacy and stability data.

Preservative-Free: The Clinical Ideal, the Engineering Challenge

For chronic therapy — glaucoma and dry eye above all — preservative-free (PF) is increasingly the clinical gold standard. Comparative trials generally show equivalent efficacy (e.g., equal IOP reduction in preserved vs PF glaucoma drops) with meaningfully better ocular surface outcomes and adherence. PF delivery takes three forms:

1. Unit-dose vials — the simplest and safest: blow-fill-seal single doses, discarded after use. Downside: higher packaging cost, more plastic waste, and patients sometimes (unsafely) save opened vials for later.
2. Novel multidose PF bottles — engineered dispensers (filter-tip or valve systems such as Aptar's Ophthalmic Squeeze Dispenser, COMOD, Novelia, 3K) that keep contents sterile without chemical preservatives, typically validated by direct tip-challenge testing with Pseudomonas, Staphylococcus and Candida. These carry meaningful device cost.
3. Reformulated PF versions of legacy molecules — PF tafluprost and PF latanoprost set the pattern in glaucoma internationally.

The market reality in India: PF unit-dose lubricants are well established, while PF chronic prescription drops remain premium-priced — an access consideration in a market where most patients pay out of pocket.

The In-Use Contamination Literature

The case both for and against preservatives ultimately rests on what happens in real bottles in real hands. A 2022 review covering 30 years of studies on in-use eye drops found microbial contamination of dropper tips and caps documented across dozens of studies, with contamination rates climbing where aseptic technique is poor and where bottles are shared or stored badly. Two lessons follow. First, preserved multidose systems are genuinely necessary — the same literature shows contaminated in-use bottles are a real infection pathway, not a theoretical one. Second, the preservative is a backstop, not a substitute for handling discipline: preservatives can be overwhelmed by heavy inoculation, BAK has weak activity against some organisms (it is poor against bacterial spores and has limited fungicidal depth), and no preservative rescues a bottle whose tip is dragged across a conjunctiva. Formulation choice and patient education have to work together.

Regulatory and Labelling Expectations

Preservative choices are increasingly visible on the regulatory radar:

• EMA (2017): mandated specific BAK warnings on product information — noting BAK may cause eye irritation, discolour soft contact lenses, and requires caution in dry eye, compromised corneas and (with particular care) paediatric use. This has become the global reference for BAK labelling.
• Pharmacopoeial requirements: preserved multidose products must pass the preservative efficacy test (USP <51>, Ph. Eur. 5.1.3, ISO 14730) during development, maintain preservative assay within limits across shelf life, and declare the preservative and its concentration on the label.
• Indian practice: the Drugs and Cosmetics Rules require declaration of preservatives on labels, and licensing authorities expect preservative efficacy data in product dossiers. As India's revised Schedule M raises sterile-manufacturing expectations, formulation files with robust preservative justification age far better under inspection than legacy assumptions.

A Note on Concentration: Less Is Usually More

BAK's ocular toxicity is concentration-dependent, and formulation science has responded: where older products used 0.01–0.02%, many modern formulations achieve preservative efficacy at 0.005% or below, and comparative studies show measurably less corneal damage at lower concentrations. Combined with once-daily dosing schedules and fixed combinations that cut total daily drop count, cumulative preservative exposure can fall substantially without abandoning the economical multidose format. When evaluating two otherwise equivalent products, the preservative concentration on the label is a legitimate — and often decisive — tiebreaker for chronic therapy.

What Prescribers and Buyers Should Actually Do

The pragmatic consensus from the literature:

• Acute, short courses: preserved multidose drops (including BAK at low concentration) are appropriate, economical and safe for most patients — e.g., a peri-operative course of Moxilux.
• Chronic daily therapy: minimise cumulative BAK exposure — prefer once-daily regimens, fixed combinations over separate bottles, and PF or alternatively-preserved options where feasible, especially in glaucoma (e.g., Travotis) and moderate-to-severe dry eye, where PF lubricants from the Restor family fit the clinical logic.
• Compromised ocular surfaces (existing dry eye, post-surgical epitheliopathy, multiple concurrent drops): treat preservative load as a clinical variable, not an afterthought.

Frequently Asked Questions

Is BAK dangerous in eye drops?

Not categorically. BAK's ocular surface toxicity is dose- and duration-dependent: short courses at typical concentrations are well tolerated by most patients. The concern is chronic, multi-drop, years-long exposure — classic in glaucoma — where evidence links BAK to epithelial damage, goblet cell loss, worsened dry eye and poorer filtration surgery outcomes. The EMA required specific BAK labelling in 2017, particularly cautioning use in neonates and compromised corneas.

What is the difference between preservative-free and "vanishing" preservatives?

Vanishing preservatives (e.g., Purite, SofZia) are chemicals that break down into benign components on contact with the tear film or light, so the eye sees little residual preservative. Preservative-free means no antimicrobial agent at all — sterility after opening is protected by the container (unit doses or engineered multidose valves), not chemistry.

Why are preservative-free eye drops more expensive?

The cost is mostly packaging and process, not the liquid: unit-dose blow-fill-seal production uses more material per dose, and multidose PF bottles contain precision valve or filter systems that must be validated by microbial challenge testing. Both also run on more specialised filling lines.

Do preservatives extend shelf life?

Preservatives protect the in-use period (the weeks after opening) far more than the sealed shelf life. An unopened bottle's shelf life is set by formulation and packaging stability, proven in ICH stability studies; the preservative system must itself remain within assay limits across that life, and must pass preservative efficacy testing to justify the labelled in-use period.

Should glaucoma patients avoid BAK entirely?

Wherever feasible, guidelines and reviews favour minimising BAK in chronic glaucoma therapy — via preservative-free or alternatively preserved formulations, fixed combinations to cut drop count, and considering laser or surgery earlier in appropriate patients. But untreated glaucoma is far more dangerous than BAK: no patient should stop prescribed drops without their ophthalmologist substituting therapy.

---

This article is for general education of healthcare and industry professionals and does not constitute medical advice. Treatment decisions belong to the treating ophthalmologist.

Evaluating our preservative philosophy or requesting formulation documentation? Contact Oculentis Medical or request product samples.